Anti-Human CD319 (SLAMF7) (Elotuzumab)

Anti-Human CD319 (SLAMF7) (Elotuzumab)

Product No.: C1060

- -
- -
Product No.C1060
Clone
HuLuc63
Target
CD319
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
SLAMF7, 19A, CD319, CRACC, CS1, SLAM family member 7
Isotype
Human IgG1κ
Applications
ELISA
,
FA
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Immunogen
Humanized antibody derived from mouse clone MuLuc63
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
ELISA,
WB,
FA,
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Elotuzumab. Elotuzumab recognizes the extracellular region of CD319 (also known as SLAMF7, CS1, and CD2-like receptor activating cytotoxic cells [CRACC]) at the membrane-proximal IgC2-like domain.
Background
CD319 is a cell surface glycoprotein that is a member of the immunoglobulin gene superfamily and is universally highly expressed on multiple myeloma (MM) cells, where it functions in human MM cell adhesion1. Since it is not detectable in healthy donor samples, CD319 has been targeted for the development of MM immunotherapy1, 2.

Elotuzumab is a humanized monoclonal antibody against CD319 that was developed as a MM immunotherapeutic1, 2. Elotuzumab was generated by immunizing female BALB/c mice with purified CD319 protein2. Spleen cells were fused to the P3X63Ag8 fusion partner, and the resulting hybridomas were screened. Murine MuLuc63 was identified as CD319 specific and Humanized.

Elotuzumab activity is mediated through antibody-dependent cellular cytotoxicity and direct NK cell activation1, 2, 3, 4. In vitro, elotuzumab inhibits binding of MM cells to bone marrow stromal cells and in vivo it inhibits tumor progression in murine xenografts and clinical trials1, 2, 4. Additionally, elotuzumab inhibits proliferation and survival of MM cells1. Elotuzumab also induces IFN-γ production3.

In flow cytometry analysis of MM samples, elotuzumab binds strongly to the majority of plasma cells2. In contrast, in healthy donors, elotuzumab primarily binds D3+CD16+CD56+ NK-like T cells, CD3-CD16+CD56+ NK cells, and approximately half of CD3+CD8+ T cells. Additionally, low levels of binding are detected on CD3+CD8- T cells and none on monocytes (CD14+HLA-DR+), B cells (CD20+HLA-DR+), or granulocytes (CD13+CD45+). Elotuzumab has been approved for the treatment of some patients with multiple myeloma 4.
Antigen Distribution
CD319 is expressed on certain healthy lymphocytes, including natural killer (NK) cells, NK-like T cells, CD8+ T cells, activated monocytes, and dendritic cells, as well as plasma cells. CD319 is highly expressed on multiple myeloma cells.
NCBI Gene Bank ID
UniProt.org
Research Area
Biosimilars
.
Cancer
.
Immunology

References & Citations

1 Tai YT, Dillon M, Song W, et al. Blood. 112(4):1329-1337. 2008.
2 Hsi ED, Steinle R, Balasa B, et al. Clin Cancer Res. 14(9):2775-2784. 2008.
3 Collins SM, Bakan CE, Swartzel GD, et al. Cancer Immunol Immunother. 62(12):1841-1849. 2013.
4 Markham A. Drugs. 76(3):397-403. 2016.
Indirect Elisa Protocol
FA
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.